Laurens Beerepoot
19-04-2023
In our profession, we need to know everything about the patient, but we also want to know as much as possible about the patient’s tumor.
Back to newsMore news
GLOW Study Ends – But WGS Remains Valuable for Glioblastoma Patients
29-09-2025
As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …
Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
10-08-2022
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …
Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
01-08-2021
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in …
It is essential to record and share data to ensure good care.
Former Minister of Health, Welfare and Sport